<DOC>
	<DOCNO>NCT00498953</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , cisplatin , fluorouracil , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Lapatinib may stop growth tumor cell block enzymes need cell growth . Giving combination chemotherapy together radiation therapy , without lapatinib , surgery may make tumor small reduce amount normal tissue need remove eliminate need surgery . PURPOSE : This phase I/II trial study side effect best dose combination chemotherapy give together radiation therapy without lapatinib see well work treat patient locally advanced cancer larynx hypopharynx .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy With Without Lapatinib Treating Patients With Locally Advanced Cancer Larynx Hypopharynx</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommend dose phase II lapatinib ditosylate patient locally advance squamous cell carcinoma larynyx hypopharynx concomitantly treat neoadjuvant induction chemotherapy comprise docetaxel , cisplatin , fluorouracil , follow chemoradiotherapy comprise carboplatin radiotherapy . ( Phase I ) - To document feasibility , framework organ preservation program , regimen patient . ( Phase II ) Secondary - To look role PET patient N1-3 disease , term PET use reliable method spare patient plan neck dissection . ( Phase II ) OUTLINE : This multicenter , dose-escalation phase I study follow randomized phase II study . Patients stratified institution EGFR status ( negative v positive ) . - Phase I : - Neoadjuvant chemotherapy : Patients receive neoadjuvant chemotherapy comprise docetaxel IV cisplatin IV day 1 fluorouracil IV continuously day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients complete partial response 4 course neoadjuvant chemotherapy proceed chemoradiotherapy . Patients less partial response course 2 course 4 proceed surgery , include total laryngectomy . - Chemoradiotherapy : Within 3 week completion neoadjuvant chemotherapy , patient undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 receive carboplatin IV day 1 , 8 , 15 , 22 , 29 , 36 , 43 . - Concurrent lapatinib ditosylate : Patients receive oral lapatinib ditosylate daily neoadjuvant chemotherapy , break neoadjuvant chemotherapy chemoradiotherapy , chemoradiotherapy . - Phase II : Patients randomize 1 2 treatment arm . - Arm I : Patients receive neoadjuvant chemotherapy undergo chemoradiotherapy phase I . - Arm II : Patients receive neoadjuvant chemotherapy undergo chemoradiotherapy phase I . Patients also receive concurrent lapatinib ditosylate phase I recommend dose determined phase I . In phase , treatment continue absence disease progression unacceptable toxicity . Patients node-positive disease ( initially ) undergo tumor blood sample collection biological study . Samples analyze ErbB-related activation via immunohistochemistry , situ hybridization , PCR/sequencing genes/proteins , detect DNA amplification polysomy ( AKT , ErbB2 , EGFR ) genomic loss ( PTEN ) via FISH , ratio EGFR EGFRvIII via QRT-PCR . Patients node-positive disease undergo least elective neck dissection evaluate negative predictive value PET scan . Patients follow every 3 month one year every 6 month thereafter .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose squamous cell carcinoma larynx hypopharynx T3 T4 disease larynx T2 , T3 T4 disease hypopharynx Nodal status must N0 , N1 , N2a , N2b , N2c N3 Resectable unresectable disease ( Phase I patient ) Patient must tumors amenable surgery ( Phase II patient ) No distant metastasis PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin &lt; 1.5 time upper limit normal range Alkaline phosphatase transaminases &lt; 2.5 time upper limit normal range Serum creatinine &lt; 1.7 mg/dL All patient ( male female ) must use effective contraception method reproductive potential ( e.g. , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , vasectomized partner ) Females must pregnant lactate Patients must normal cardiac function ( LVEF assess MUGA ECHO ) clinically satisfactory 12lead ECG No serious cardiac illness medical condition within past 6 month include , limited , follow : History document congestive heart failure Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( e.g. , systolic BP &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) Patients able swallow oral agent No current malignancy sit exception cone biopsied carcinoma cervix adequately treat basal squamous cell skin carcinoma cancer patient diseasefree least five year Absence unstable systemic disease active uncontrolled infection Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : No prior therapy head neck cancer More 10 day since prior concurrent CYP3A4 inducer , include follow : Antibiotics ( e.g. , rifamycin class agent [ rifampicin , rifabutin , rifapentine ] ) Anticonvulsants ( e.g. , phenytoin , carbamezepine , barbiturates [ phenobarbital ] ) Oral glucocorticoid ( e.g. , cortisone [ &gt; 50 mg ] , hydrocortisone [ &gt; 40 mg ] , prednisone [ &gt; 10 mg ] , methylprednisolone [ &gt; 8 mg ] , dexamethasone [ &gt; 1.5 mg ] ) Antiretrovirals ( e.g. , efavirenz nevirapine ) Other ( hypericum perforatum [ St. John 's Wort ] modafinil ) More 10 day since prior concurrent CYP3A4 inhibitor , include follow : Antibiotics ( e.g. , clarithromycin , erythromycin , troleandomycin ) Antifungals ( e.g. , itraconazole , ketoconazole , fluconazole [ &gt; 150 mg daily ] , voriconazole ) Antiretrovirals protease inhibitor ( e.g. , delavirdine , nelfinavir , amprenavir , ritonavir , indinavir , saquinavir , lopinavir ) Calcium channel blocker ( e.g. , verapamil diltiazem ) Antidepressants ( e.g. , nefazodone fluvoxamine ) Gastrointestinal agent ( e.g. , cimetidine aprepitant ) Other ( e.g. , grapefruit , grapefruit juice , camiodarone ) Miscellaneous ( e.g. , antacid [ Mylanta , Maalox , Tums , Rennies ] , herbal [ bergamottin glabridin ] dietary supplement ) Patients may receive anticancer therapy investigational agent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>